{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:47:51Z","timestamp":1791996471751,"version":"4.4.0"},"reference-count":84,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living &gt;5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and\/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2022.0047","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T15:38:00Z","timestamp":1662651480000},"page":"972-980","source":"Crossref","is-referenced-by-count":394,"title":["NCCN Guidelines\u00ae Insights: Ovarian Cancer, Version 3.2022"],"prefix":"10.6004","volume":"20","author":[{"given":"Deborah K.","family":"Armstrong","sequence":"first","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"2Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor J.","family":"Backes","sequence":"additional","affiliation":[{"name":"3The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Bakkum-Gamez","sequence":"additional","affiliation":[{"name":"4Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[{"name":"5University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[{"name":"6University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Berchuck","sequence":"additional","affiliation":[{"name":"7Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-may","family":"Chen","sequence":"additional","affiliation":[{"name":"8UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola C.","family":"Chitiyo","sequence":"additional","affiliation":[{"name":"9Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[{"name":"10City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"DeRosa","sequence":"additional","affiliation":[{"name":"11Patient advocate;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"12Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[{"name":"13The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[{"name":"14University of Washington\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Grisham","sequence":"additional","affiliation":[{"name":"9Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeshir","family":"Hakam","sequence":"additional","affiliation":[{"name":"15Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Jain","sequence":"additional","affiliation":[{"name":"16Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Karam","sequence":"additional","affiliation":[{"name":"17Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[{"name":"18UCLA Jonsson Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Leath III","sequence":"additional","affiliation":[{"name":"19O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Leiserowitz","sequence":"additional","affiliation":[{"name":"20UC Davis Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Liu","sequence":"additional","affiliation":[{"name":"21Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie","family":"Martin","sequence":"additional","affiliation":[{"name":"22Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[{"name":"23Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McHale","sequence":"additional","affiliation":[{"name":"24UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McLean","sequence":"additional","affiliation":[{"name":"25University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[{"name":"26UT Southwestern Simmons Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Percac-Lima","sequence":"additional","affiliation":[{"name":"12Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Remmenga","sequence":"additional","affiliation":[{"name":"27Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schorge","sequence":"additional","affiliation":[{"name":"28St. Jude Children's Research Hospital\/The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Stewart","sequence":"additional","affiliation":[{"name":"10City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[{"name":"29Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vargas","sequence":"additional","affiliation":[{"name":"30Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Wahner","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"4Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Werner","sequence":"additional","affiliation":[{"name":"31Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Zsiros","sequence":"additional","affiliation":[{"name":"32Roswell Park Comprehensive Cancer Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"33National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hang","sequence":"additional","affiliation":[{"name":"33National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref841","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas","volume":"24","author":"Gourley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas","volume":"24","author":"Gourley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","article-title":"A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer: a Multicentre Italian Trial in Ovarian cancer (MITO-5) study","volume":"66","author":"Pignata","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref471","article-title":"tablets prescribing information New Jersey Pharmaceuticals Corporation","author":"Mekinist","year":"2022","journal-title":"East"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref861","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1002\/cncr.31027","article-title":"Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study","volume":"123","author":"Stewart","year":"2017","journal-title":"Cancer"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref951","article-title":"capsules prescribing information New Jersey Pharmaceuticals Corporation","author":"Tafinlar","year":"2022","journal-title":"East"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann Oncol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged \u226570 years with advanced ovarian cancer\u2014a study by the AGO OVAR Germany","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann Oncol"},{"key":"ref121","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.5508","article-title":"EWOC-1: a randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): a GCIG-ENGOT-GINECO study [abstract]","volume":"37","author":"Falandry","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann Oncol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","article-title":"Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO\/GCIG randomized clinical trial","volume":"7","author":"Falandry","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref371","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","article-title":"A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer: a Multicentre Italian Trial in Ovarian cancer (MITO-5) study","volume":"66","author":"Pignata","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdi368","article-title":"Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study","volume":"16","author":"Freyer","year":"2005","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","article-title":"Patterns and progress in ovarian cancer over 14 years","volume":"108","author":"Chan","year":"2006","journal-title":"Obstet Gynecol"},{"key":"ref611","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.5508","article-title":"EWOC-1: a randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): a GCIG-ENGOT-GINECO study [abstract]","volume":"37","author":"Falandry","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdl400","article-title":"Carboplatin\/cyclophosphamide or carboplatin\/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens","volume":"18","author":"Tr\u00e9dan","year":"2007","journal-title":"Ann Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum Pathol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","article-title":"Patterns and progress in ovarian cancer over 14 years","volume":"108","author":"Chan","year":"2006","journal-title":"Obstet Gynecol"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdi368","article-title":"Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study","volume":"16","author":"Freyer","year":"2005","journal-title":"Ann Oncol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdl400","article-title":"Carboplatin\/cyclophosphamide or carboplatin\/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens","volume":"18","author":"Tr\u00e9dan","year":"2007","journal-title":"Ann Oncol"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2010.34.1552","article-title":"Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer","volume":"29","author":"Fairfield","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/IGC.0000000000001221","article-title":"Safety and efficacy of extended bevacizumab therapy in elderly (\u226570 years) versus younger patients treated for newly diagnosed ovarian cancer in the international ROSiA study","volume":"28","author":"Selle","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2010.34.1552","article-title":"Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer","volume":"29","author":"Fairfield","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1002\/cncr.31027","article-title":"Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study","volume":"123","author":"Stewart","year":"2017","journal-title":"Cancer"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","article-title":"Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO\/GCIG randomized clinical trial","volume":"7","author":"Falandry","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged \u226570 years with advanced ovarian cancer\u2014a study by the AGO OVAR Germany","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann Oncol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J Pathol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"X111","DOI":"10.1093\/annonc\/mds300","article-title":"New insights into ovarian cancer pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Ann Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum Pathol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2016.03.018","article-title":"Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials","volume":"143","author":"Tinquaut","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2016.03.018","article-title":"Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials","volume":"143","author":"Tinquaut","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/IGC.0000000000001221","article-title":"Safety and efficacy of extended bevacizumab therapy in elderly (\u226570 years) versus younger patients treated for newly diagnosed ovarian cancer in the international ROSiA study","volume":"28","author":"Selle","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1055-9965.EPI-17-0290","article-title":"Recent trends in ovarian cancer incidence and relative survival in the United States by race\/ethnicity and histologic subtypes","volume":"26","author":"Park","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2016.11.033","article-title":"Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer \u2013 an NRG oncology\/Gynecologic Oncology Group study","volume":"144","author":"von Gruenigen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1055-9965.EPI-17-0290","article-title":"Recent trends in ovarian cancer incidence and relative survival in the United States by race\/ethnicity and histologic subtypes","volume":"26","author":"Park","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J Pathol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"X111","DOI":"10.1093\/annonc\/mds300","article-title":"New insights into ovarian cancer pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Ann Oncol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref461","article-title":"capsules prescribing information New Jersey Pharmaceuticals Corporation","author":"Tafinlar","year":"2022","journal-title":"East"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2016.11.033","article-title":"Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer \u2013 an NRG oncology\/Gynecologic Oncology Group study","volume":"144","author":"von Gruenigen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref961","article-title":"tablets prescribing information New Jersey Pharmaceuticals Corporation","author":"Mekinist","year":"2022","journal-title":"East"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/9\/article-p972.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/9\/article-p972.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T15:40:10Z","timestamp":1662738010000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/9\/article-p972.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":84,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.0047","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}